Pembrolizumab May Be Associated with Sustainable Relapse-Free Survival in High-Risk Melanoma
November 8th 2021After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.